When a patient comes to me after years of struggling with obesity, the first thing I notice is how relieved they are that I’m not going to tell them to “eat less and move more.” They’ve heard that a hundred times. What they haven’t had is a physician who actually examines the mechanisms behind why that advice hasn’t worked for them—and that difference defines almost everything about how I practice.
Primary care physicians carry enormous responsibility for a broad patient panel. They manage hypertension, diabetes, anxiety, infections, preventive care, and a dozen other concerns in a single visit. Obesity often surfaces as a line item—a BMI note in the chart, a gentle nudge toward a referral. I don’t say this critically; it reflects the reality of primary care bandwidth. But treating obesity as a chronic, multifactorial disease requires a depth of focus that a fifteen-minute visit simply can’t support.
The Evaluation Is the Treatment
The single biggest misconception about obesity medicine is that the physician’s job is to prescribe a medication and step back. The evaluation itself—if done correctly—is therapeutic. When I see a new patient, I want to understand their weight history from adolescence forward. Did they gain weight after a specific event? A pregnancy, a surgery, a medication change, a period of chronic stress? The trajectory tells me more than the current number on the scale.
I ask about sleep in detail—not “Do you sleep well?” but “What time do you fall asleep, what wakes you, do you snore, has anyone observed you stop breathing?” Untreated obstructive sleep apnea drives insulin resistance and cortisol dysregulation in ways that make weight loss pharmacologically and behaviorally harder. I’ve had patients who failed three prior medication trials simply because their sleep disorder wasn’t identified. Once that was addressed, the same class of medication worked.
I also ask about medications—every medication. Beta-blockers, certain antidepressants, antipsychotics, insulin secretagogues, corticosteroids, and several anticonvulsants are meaningfully obesogenic. A patient on two of those simultaneously is fighting pharmacology as much as biology. Before I add anything to that regimen, I want to know whether something can come off, or whether we need to time our intervention around a medication taper.
Metabolic Assessment Isn’t Optional
I order labs that aren’t always standard in a primary care workup for weight. A fasting insulin alongside fasting glucose gives me a far clearer picture of insulin resistance than glucose alone. I look at thyroid function, but I also look at reverse T3 in patients who’ve been through significant caloric restriction before—adaptive thermogenesis can suppress metabolic rate in ways that make a normal TSH misleading. I check uric acid, which tracks closely with fructose metabolism and metabolic syndrome severity. I look at inflammatory markers when the history suggests chronic inflammation is a driver.
This isn’t about ordering every test available—it’s about asking a specific clinical question and finding the right data point to answer it. When a patient’s response to dietary intervention is flat despite genuine adherence, I want a metabolic explanation before I assume the problem is behavioral.
The Prescription Is the Last Step, Not the First
Experienced weight loss physicians know that a prescription without context is a gamble. GLP-1 receptor agonists—semaglutide, tirzepatide, and others in this class—are genuinely effective medications, but they work differently depending on the patient’s underlying physiology, eating patterns, and what we’re trying to accomplish beyond the number on the scale. I want to know whether someone has a history of gastroparesis before I start a medication that slows gastric emptying. I want to know about their personal or family history of thyroid tumors. I want to understand their relationship with food—whether there’s restriction and compensation cycling, whether food is serving an emotional regulation function—because if it is, we need to address that in parallel, not after.
I also don’t start at the highest dose we might eventually reach. Titration is a strategy, not just a safety protocol. How a patient tolerates the early dose tells me something about how their gastrointestinal system responds, and that shapes the pace of escalation and the eventual maintenance dose. A patient who is nauseated and miserable at 0.5mg is not going to stay on this medication at 2.4mg.
Prior Authorizations and Insurance: A Different Approach
One practical difference between obesity specialists and generalists that patients rarely anticipate is how we handle the insurance side of treatment. Prior authorizations for anti-obesity medications are notoriously difficult. The denial criteria are often boilerplate, and appeals succeed at meaningful rates when the documentation specifically addresses the insurer’s stated criteria.
I document comorbidities using the language that insurers recognize—not “obesity” in isolation, but obesity with associated hypertension, prediabetes, obstructive sleep apnea, or osteoarthritis of the weight-bearing joints. I document prior attempts at supervised intervention. I note functional impairment. This isn’t gaming the system; it’s accurately representing the clinical picture in the terms the reviewing physician on the other end is actually applying. A primary care physician who has sixty patients waiting and isn’t deeply familiar with obesity medication PA criteria is unlikely to have the time to build that documentation systematically.
What to Look for When Choosing a Physician
If you’re looking for an obesity medicine specialist, a few things are worth evaluating. Board certification through the American Board of Obesity Medicine (ABOM) is the clearest credential—it requires a structured examination and ongoing continuing medical education specific to obesity medicine. It doesn’t guarantee a good physician, but it filters for one who has invested in the field.
Ask whether the practice conducts a comprehensive initial evaluation or moves quickly to prescribing. Ask how they handle medication side effects—not just what to do if they occur, but what the follow-up schedule looks like in the first three months. Ask whether behavioral support is part of the model. A practice that prescribes medication without any discussion of eating patterns, sleep, or stress is leaving a significant portion of the treatment on the table.
Be cautious about practices that lead with a specific medication before they’ve evaluated you. The medication should follow the assessment, not precede it. And be cautious about practices that set an aggressive weight loss rate as the primary goal—very rapid loss, particularly without attention to lean mass preservation, often sets patients up for regain and metabolic adaptation that makes the next attempt harder.
Obesity is a chronic condition. The physician managing it should approach it with the same longitudinal mindset they’d bring to managing hypertension or type 2 diabetes—with regular reassessment, adjustment of the treatment plan as physiology and circumstances change, and a genuine understanding that the goal isn’t a number on a scale. The goal is a sustainable, healthier trajectory for the person in front of you.
About Dr. Quoc N. Dang, DO
Dr. Quoc N. Dang, DO, is a board-certified physician and medical director at WeightLossPills.com, where he specializes in medically supervised weight management and GLP-1 therapy.
